$RCEL
AVITA Medical, Inc. Stock $rcel

$rcel Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024018748 Filed on February 22, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$11.10M	$14.20M	$50.14M
YoY Change	5.25%	50.13%	45.68%
Cost Of Revenue	$1.513M	$1.796M	$7.780M
YoY Change	-9.24%	42.99%	28.79%
Gross Profit	$9.591M	$12.40M	$42.36M
YoY Change	7.97%	51.23%	49.27%
Gross Profit Margin	86.37%	87.35%	84.48%
Selling, General & Admin	$21.60M	$17.97M	$65.63M
YoY Change	45.62%	54.04%	45.05%
% of Gross Profit	225.24%	144.9%	154.91%
Research & Development	$5.194M	$6.765M	$20.82M
YoY Change	13.26%	100.21%	50.26%
% of Gross Profit	54.15%	54.56%	49.15%
Depreciation & Amortization	$203.0K	$182.0K	$632.0K
YoY Change	50.37%	40.0%	11.27%
% of Gross Profit	2.12%	1.47%	1.49%
Operating Expenses	$26.80M	$24.67M	$86.45M
YoY Change	37.98%	76.03%	46.27%
Operating Profit	-$17.21M	-$12.27M	-$42.66M
YoY Change	73.61%	110.99%	55.08%
Interest Expense	$1.356M	-$1.122M	$1.143M
YoY Change	33800.0%	18600.0%	7043.75%
% of Operating Profit
Other Income/Expense, Net	-$66.00K	$6.342M	$8.483M
YoY Change	-109.1%	984.1%	851.01%
Pretax Income	-$18.63M	-$7.053M	-$35.32M
YoY Change	102.7%	32.35%	32.62%
Income Tax	$30.00K	$12.00K	$66.00K
% Of Pretax Income
Net Earnings	-$18.66M	-$7.065M	-$35.38M
YoY Change	102.36%	31.98%	32.69%
Net Earnings / Revenue	-168.03%	-49.77%	-70.56%
Basic Earnings Per Share	-$0.73		$1.40
Diluted Earnings Per Share	-$0.73	-$0.28	$1.40
COMMON SHARES
Basic Shares Outstanding	25.71M	25.55M	25.33M
Diluted Shares Outstanding	25.64M		25.33M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$68.18M	$89.06M	$89.06M
YoY Change	-7.17%	12.24%	12.24%
Cash & Equivalents	$16.95M	$22.12M	$22.12M
Short-Term Investments	$51.23M	$66.94M	$66.94M
Other Short-Term Assets	$135.0K	$18.00K	$1.414M
YoY Change	365.52%	-85.83%	37.15%
Inventory	$7.171M	$5.596M	$5.596M
Prepaid Expenses	$1.216M	$1.376M
Receivables	$7.081M	$7.664M	$7.891M
Other Receivables	$28.00K	$30.00K	$48.00K
Total Short-Term Assets	$85.99M	$104.0M	$104.0M
YoY Change	3.9%	18.92%	18.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.297M	$1.877M	$4.317M
YoY Change	222.36%	56.42%	110.48%
Goodwill
YoY Change
Intangibles	$542.0K	$487.0K
YoY Change	17.57%	4.73%
Long-Term Investments		$0.00
YoY Change		-100.0%
Other Assets	$401.0K	$355.0K	$2.830M
YoY Change	74.35%	190.98%	108.09%
Total Long-Term Assets	$11.40M	$7.634M	$7.634M
YoY Change	15.56%	-29.35%	-29.35%
TOTAL ASSETS
Total Short-Term Assets	$85.99M	$104.0M	$104.0M
Total Long-Term Assets	$11.40M	$7.634M	$7.634M
Total Assets	$97.38M	$111.6M	$111.6M
YoY Change	5.14%	13.61%	13.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.477M	$3.793M	$3.793M
YoY Change	19.32%	26.35%	26.35%
Accrued Expenses	$6.706M	$7.972M	$8.867M
YoY Change	55.84%	10.19%	22.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.86M	$13.20M	$13.20M
YoY Change	3.27%	23.44%	23.44%
LONG-TERM LIABILITIES
Long-Term Debt	$41.30M	$39.81M	$39.81M
YoY Change
Other Long-Term Liabilities	$11.65M	$9.573M	$9.573M
YoY Change	225.85%	238.15%	238.15%
Total Long-Term Liabilities	$41.30M	$39.81M	$49.39M
YoY Change	1055.27%	1306.29%	1644.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.86M	$13.20M	$13.20M
Total Long-Term Liabilities	$41.30M	$39.81M	$49.39M
Total Liabilities	$63.99M	$61.89M	$62.58M
YoY Change	348.45%	377.3%	362.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$316.6M	-$298.0M
YoY Change	16.49%	13.47%
Common Stock	$3.000K	$3.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$32.57M	$49.06M	$49.06M
YoY Change
Total Liabilities & Shareholders Equity	$97.38M	$111.6M	$111.6M
YoY Change	5.14%	13.61%	13.61%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$18.66M	-$7.065M	-$35.38M
YoY Change	102.36%	31.98%	32.69%
Depreciation, Depletion And Amortization	$203.0K	$182.0K	$632.0K
YoY Change	50.37%	40.0%	11.27%
Cash From Operating Activities	-$20.86M	-$10.86M	-$38.01M
YoY Change	129.96%	216.09%	99.11%
INVESTING ACTIVITIES
Capital Expenditures	$1.147M	$291.0K	$1.381M
YoY Change	303.87%	315.71%	205.53%
Acquisitions
YoY Change
Other Investing Activities	$16.21M	-$57.01M	$2.988M
YoY Change	-14.99%	1746.24%	-115.83%
Cash From Investing Activities	$15.07M	-$57.30M	$1.607M
YoY Change	-19.81%	1714.53%	-108.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	631.0K	39.43M	40.37M
YoY Change	269.01%	4286.43%	4386.0%
NET CHANGE
Cash From Operating Activities	-20.86M	-10.86M	-38.01M
Cash From Investing Activities	15.07M	-57.30M	1.607M
Cash From Financing Activities	631.0K	39.43M	40.37M
Net Change In Cash	-5.167M	-28.73M	3.954M
YoY Change	-152.27%	404.48%	-110.53%
FREE CASH FLOW
Cash From Operating Activities	-$20.86M	-$10.86M	-$38.01M
Capital Expenditures	$1.147M	$291.0K	$1.381M
Free Cash Flow	-$22.01M	-$11.15M	-$39.39M
YoY Change	135.24%	218.08%	101.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001762303
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	us-gaap	Impairment Of Intangible Asset Indefinite Lived Excluding Goodwill Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#OperatingIncomeLoss
CY2023Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://avitamedical.com/20231231#ContractualMaturitiesMember
CY2022Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://avitamedical.com/20231231#ContractualMaturitiesMember
CY2022Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://avitamedical.com/20231231#ContractualMaturitiesMember
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023	us-gaap	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39059
CY2023	dei	Entity Registrant Name EntityRegistrantName	AVITA MEDICAL, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1021707
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	28159 Avenue Stanford
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 220
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Valencia
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91355
CY2023	dei	City Area Code CityAreaCode	661
CY2023	dei	Local Phone Number LocalPhoneNumber	367-9170
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	RCEL
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	431861022
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25706662
CY2023	dei	Auditor Firm AuditorFirmId	248
CY2023	dei	Auditor Name AuditorName	GRANT THORNTON LLP
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22118000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18164000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	66939000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	61178000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7664000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3515000
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	30000
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	898000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1659000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1578000
CY2023Q4	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	5596000
CY2022Q4	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	2125000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	104006000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	87458000
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	6930000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1877000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1200000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2440000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	851000
CY2023Q4	rcel	Corporate Owned Life Insurance Asset CorporateOwnedLifeInsuranceAsset	2475000
CY2022Q4	rcel	Corporate Owned Life Insurance Asset CorporateOwnedLifeInsuranceAsset	1238000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	487000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	465000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	355000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	122000
CY2023Q4	us-gaap	Assets Assets	111640000
CY2022Q4	us-gaap	Assets Assets	98264000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3793000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3002000
CY2023Q4	rcel	Accrued Wages And Fringe Benefits AccruedWagesAndFringeBenefits	7972000
CY2022Q4	rcel	Accrued Wages And Fringe Benefits AccruedWagesAndFringeBenefits	6623000
CY2023Q4	rcel	Non Qualified Deferred Compensation Plan Liability Current NonQualifiedDeferredCompensationPlanLiabilityCurrent	168000
CY2022Q4	rcel	Non Qualified Deferred Compensation Plan Liability Current NonQualifiedDeferredCompensationPlanLiabilityCurrent	78000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1266000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	990000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13199000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10693000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	39812000
CY2023Q4	rcel	Non Qualified Deferred Compensation Plan Liability NonQualifiedDeferredCompensationPlanLiability	3663000
CY2022Q4	rcel	Non Qualified Deferred Compensation Plan Liability NonQualifiedDeferredCompensationPlanLiability	1270000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	357000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	698000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1702000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	306000
CY2023Q4	rcel	Warrant Liability WarrantLiability	3158000
CY2023Q4	us-gaap	Liabilities Liabilities	61891000
CY2022Q4	us-gaap	Liabilities Liabilities	12967000
CY2023Q4	rcel	Non Qualified Deferred Compensation Plan Share Awards NonQualifiedDeferredCompensationPlanShareAwards	693000
CY2022Q4	rcel	Non Qualified Deferred Compensation Plan Share Awards NonQualifiedDeferredCompensationPlanShareAwards	557000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25682078
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25682078
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25208436
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25208436
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	rcel	Common Stock Held By Non Qualified Deferred Compensation Plan CommonStockHeldByNonQualifiedDeferredCompensationPlan	-1130000
CY2022Q4	rcel	Common Stock Held By Non Qualified Deferred Compensation Plan CommonStockHeldByNonQualifiedDeferredCompensationPlan	-127000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	350039000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	339825000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1887000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7627000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-297969000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-262588000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	49056000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	84740000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	111640000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	98264000
CY2023	us-gaap	Revenues Revenues	50143000
CY2022	us-gaap	Revenues Revenues	34421000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	7780000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	6041000
CY2023	us-gaap	Gross Profit GrossProfit	42363000
CY2022	us-gaap	Gross Profit GrossProfit	28380000
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1428000
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	3215000
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	37291000
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	21913000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28334000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23330000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20821000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13857000
CY2023	us-gaap	Operating Expenses OperatingExpenses	86446000
CY2022	us-gaap	Operating Expenses OperatingExpenses	59100000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-42655000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-27505000
CY2023	us-gaap	Interest Expense InterestExpense	1143000
CY2022	us-gaap	Interest Expense InterestExpense	16000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8483000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	892000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35315000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26629000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35381000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26665000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.4
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.4
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.07
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.07
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25331264
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25331264
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25000180
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25000180
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35381000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26665000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-111000
CY2023	rcel	Cumulative Translation Adjustments Recognized In Earnings As Part Of The Reorganization Of Foreign Subsidiaries CumulativeTranslationAdjustmentsRecognizedInEarningsAsPartOfTheReorganizationOfForeignSubsidiaries	-9415000
CY2023	rcel	Change In Fair Value Due To Credit Risk On Long Term Debt ChangeInFairValueDueToCreditRiskOnLongTermDebt	-621000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	522000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-322000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44895000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27098000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	104624000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26665000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6527000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	900000
CY2022	rcel	Change In Classification Of Deferred Compensation Share Awards ChangeInClassificationOfDeferredCompensationShareAwards	-192000
CY2022	rcel	Change In Redemption Value Of Share Awards In Nqdc Plan ChangeInRedemptionValueOfShareAwardsInNQDCPlan	-21000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-433000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	84740000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35381000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7866000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	957000
CY2023	rcel	Distribution Diversification Of Common Stock Held By The Nqdc Plan DistributionDiversificationOfCommonStockHeldByTheNqdcPlan	752000
CY2023	rcel	Change In Redemption Value Of Share Awards In Nqdc Plan ChangeInRedemptionValueOfShareAwardsInNQDCPlan	-1019000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	655000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	522000
CY2023	rcel	Change In Fair Value Due To Credit Risk On Long Term Debt ChangeInFairValueDueToCreditRiskOnLongTermDebt	-621000
CY2023	rcel	Cumulative Translation Adjustments Recognized In Earnings As Part Of The Reorganization Of Foreign Subsidiaries CumulativeTranslationAdjustmentsRecognizedInEarningsAsPartOfTheReorganizationOfForeignSubsidiaries	-9415000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	49056000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35381000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26665000
CY2023	rcel	Cumulative Translation Adjustments Recognized In Earnings As Part Of Reorganization Of Foreign Subsidiaries CumulativeTranslationAdjustmentsRecognizedInEarningsAsPartOfReorganizationOfForeignSubsidiaries	9415000
CY2023	rcel	Loss On Issuance Under Credit Agreement LossOnIssuanceUnderCreditAgreement	1238000
CY2023	rcel	Change In Fair Value Of Long Term Debt ChangeInFairValueOfLongTermDebt	1616000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	733000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	632000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	568000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	8384000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	6998000
CY2023	rcel	Non Cash Lease Expense NonCashLeaseExpense	748000
CY2022	rcel	Non Cash Lease Expense NonCashLeaseExpense	692000
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-83000
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-3000
CY2023	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	17000
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	4000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-37000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	85000
CY2023	rcel	Excess And Obsolete Inventory Related Charges ExcessAndObsoleteInventoryRelatedCharges	-221000
CY2022	rcel	Excess And Obsolete Inventory Related Charges ExcessAndObsoleteInventoryRelatedCharges	-375000
CY2023	rcel	Estimated Deferred Costs EstimatedDeferredCosts	-194000
CY2022	rcel	Estimated Deferred Costs EstimatedDeferredCosts	130000
CY2023	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	341000
CY2022	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	338000
CY2023	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	24000
CY2022	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	-5000
CY2023	rcel	Amortization Of Premium Of Marketable Securities AmortizationOfPremiumOfMarketableSecurities	-1381000
CY2022	rcel	Amortization Of Premium Of Marketable Securities AmortizationOfPremiumOfMarketableSecurities	-281000
CY2023	rcel	Non Cash Changes In Fair Value Of Non Qualified Deferred Compensation Plan NonCashChangesInFairValueOfNonQualifiedDeferredCompensationPlan	-856000
CY2022	rcel	Non Cash Changes In Fair Value Of Non Qualified Deferred Compensation Plan NonCashChangesInFairValueOfNonQualifiedDeferredCompensationPlan	-38000
CY2023	rcel	Increase Decrease In Trade And Other Receivables IncreaseDecreaseInTradeAndOtherReceivables	-4172000
CY2022	rcel	Increase Decrease In Trade And Other Receivables IncreaseDecreaseInTradeAndOtherReceivables	-395000
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-868000
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	590000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	451000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	366000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3693000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	371000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-713000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-720000
CY2023	rcel	Increase Decrease In Corporate Owned Life Insurance Asset IncreaseDecreaseInCorporateOwnedLifeInsuranceAsset	1008000
CY2022	rcel	Increase Decrease In Corporate Owned Life Insurance Asset IncreaseDecreaseInCorporateOwnedLifeInsuranceAsset	1084000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	233000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-178000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	809000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	282000
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1347000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1272000
CY2023	rcel	Increase Decrease In Current Non Qualified Deferred Compensation Liability IncreaseDecreaseInCurrentNonQualifiedDeferredCompensationLiability	-1504000
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	266000
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-92000
CY2023	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	2251000
CY2022	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	994000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-341000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-254000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-50000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38011000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19090000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	78757000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	74362000
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2372000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	79439000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	55555000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1381000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	452000
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	66000
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	73000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1607000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19332000
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	38762000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	957000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	900000
CY2023	rcel	Employee Stock Purchase Plan Espp Purchases EmployeeStockPurchasePlanEsppPurchases	655000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40374000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	900000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-16000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-26000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3954000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-37548000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18164000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55712000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22118000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18164000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	44000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	17000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1143000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	15000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	33000
CY2023	rcel	Right Of Use Asset Obtained In Exchange For Lease Liabilities RightOfUseAssetObtainedInExchangeForLeaseLiabilities	2337000
CY2023	rcel	Warrant Liability Recognized Upon Issuance Of Term Loan WarrantLiabilityRecognizedUponIssuanceOfTermLoan	2425000
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassification of prior year presentation</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain prior year amounts within Other current liabilities have been reclassified to Current non-qualified deferred compensation liability, in the Consolidated Balance Sheets for consistency with current period presentation. These reclassifications had no effect on the reported results of operations or financial position.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	rcel	Non Qualified Deferred Compensation Share Awards Policy Textblock NonQualifiedDeferredCompensationShareAwardsPolicyTextblock	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Qualified Deferred Compensation Stock Awards</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with ASC 718</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, Compensation — Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the deferred RSU awards under the NQDC plan are classified as an equity instrument and changes in fair value of the amount owed to the participant are not recognized. As the plan permits diversification, presentation outside of permanent equity in accordance with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ASR 268, Redeemable Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is appropriate. The redemption amounts are based on the vested percentage and are recorded outside of equity as Non-qualified deferred compensation share awards on the Consolidated Balance Sheets. Deferred awards will be presented outside of permanent equity until the awards are vested. For further details refer to Note 18.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts (including allowance for credit losses, carrying value of long-lived assets, the useful lives of long-lived assets, accounting for marketable securities, income taxes, fair value of the debt, fair value of warrants, stock-based compensation and the stand-alone selling price for the BARDA contract) and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	rcel	Contract Description ContractDescription	For revenues related to the BARDA contract within the scope of ASC 606, the Company identified two performance obligations (i) the procurement of 5,614 RECELL units, (ii) emergency preparedness services.
CY2023	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	30 days
CY2023Q4	rcel	Cash At Deposit Institutions CashAtDepositInstitutions	10700000
CY2022Q4	rcel	Cash At Deposit Institutions CashAtDepositInstitutions	4100000
CY2023Q4	rcel	Cash In Foreign Institutions CashInForeignInstitutions	69000
CY2022Q4	rcel	Cash In Foreign Institutions CashInForeignInstitutions	737000
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	11400000
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	14100000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, BARDA receivables and other receivables. As of December 31, 2023 and 2022, substantially all of the Company’s cash was deposited in accounts at financial institutions, and amounts may exceed federally insured limits and subject to the risk of bank failure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> single commercial customer accounted for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of accounts receivable. As of December 31, 2022, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> commercial customer accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of net accounts receivable. For the year-ended December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> single commercial customer accounted for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of total revenues. For the year-ended December 31, 2022, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> commercial customer accounted for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of total revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BARDA revenues for the procurement of the RECELL system accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of total revenues for the years-ended December 31, 2023 and 2022, respectively. BARDA receivables for the procurement of the RECELL system and emergency preparedness accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of BARDA receivables as of December 31, 2023 and 2022, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See table below for breakdown of BARDA receivables (in thousands).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div style="font-size:10pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:51.71%;"></td> <td style="width:1%;"></td> <td style="width:21.336%;"></td> <td style="width:1%;"></td> <td style="width:2.02%;"></td> <td style="width:1%;"></td> <td style="width:20.936%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">BARDA procurement and emergency preparedness services</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">BARDA expense reimbursements</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">882</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">30</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">898</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table></div>
CY2023Q4	rcel	Procurement And Emergency Preparedness ProcurementAndEmergencyPreparedness	8000
CY2022Q4	rcel	Procurement And Emergency Preparedness ProcurementAndEmergencyPreparedness	16000
CY2023Q4	rcel	Expense Reimbursements ExpenseReimbursements	22000
CY2022Q4	rcel	Expense Reimbursements ExpenseReimbursements	882000
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	30000
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	898000
CY2023Q4	us-gaap	Warrants And Rights Outstanding Measurement Input WarrantsAndRightsOutstandingMeasurementInput	0
CY2023	rcel	Description Of Maturity Terms DescriptionOfMaturityTerms	We classify all highly liquid investments with original maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. The Company classifies marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date, and as long-term when the investments have remaining contractual maturities of more than one year from the balance sheet date.
CY2023	rcel	Marketable Securities Final Maturity Period MarketableSecuritiesFinalMaturityPeriod	P37M
CY2022	us-gaap	Advertising Expense AdvertisingExpense	216000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	48000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	24000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	24000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	28000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	24000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5000
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	9000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	48000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	24000
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2023Q4	rcel	Capitalized Patent Costs CapitalizedPatentCosts	616000
CY2022Q4	rcel	Capitalized Patent Costs CapitalizedPatentCosts	558000
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	4000
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	us-gaap	Advertising Expense AdvertisingExpense	398000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023	rcel	Non Qualified Deferred Compensation Plan Liability And Corporate Owned Life Insurance Asset Policy Textblock NonQualifiedDeferredCompensationPlanLiabilityAndCorporateOwnedLifeInsuranceAssetPolicyTextblock	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Qualified Deferred Compensation Plan Liability and Corporate-Owned Life Insurance Asset</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s non-qualified deferred compensation plan (the "NQDC plan"), which became effective in October 2021, allows highly compensated key employees to elect to defer a portion of their salary, bonus and RSU awards to later years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management determined that the cash deferrals under the NQDC plan shall be accounted for similarly to a defined benefit plan under ASC 715, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation – Retirement Benefits </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(“ASC 715”), and should follow accounting treatment that is similar to a cash balance plan. Management determined that the employee portion and employer portion of the deferred </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compensation should be recognized as a compensation expense with a corresponding credit to deferred compensation liability. The matching contribution will be accrued over the vesting period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% vesting in the first year and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% vesting in the second year. Employees aged 55 or older immediately vest in employer matching contributions. The change in the liability between each reporting period is accounted for as compensation expense with a corresponding adjustment to deferred compensation liability. Upon distribution, the Company will record the distribution as a decrease to deferred compensation liability with a corresponding cre</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">dit to cash. The Company funds the NQDC plan through a Corporate-Owned Life Insurance (“COLI”). Per the ASC 325-30-25-1A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, Investments – Other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, COLI is recorded as an asset on the Consolidated Balance Sheets as it does not meet the definition of a plan asset under ASC 715. The Company invests in COLI policies relating to its deferred compensation plan. Investments in COLI policies are recorded at their cash surrender values as of each balance sheet date. Changes in the cash surrender value during the period are recorded as a gain or loss in the Consolidated Statements of Operations in Other income, net.</span></p>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	66844000
CY2023Q4	rcel	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	100000
CY2023Q4	rcel	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent	5000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	66939000
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	61601000
CY2022Q4	rcel	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	1000
CY2022Q4	rcel	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent	424000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	61178000
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	6933000
CY2022Q4	rcel	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	7000
CY2022Q4	rcel	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	10000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	6930000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	66844000
CY2023Q4	rcel	Available For Sale Securities Debt Maturities Within One Year Carrying Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearCarryingValue	66939000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	61601000
CY2022Q4	rcel	Available For Sale Securities Debt Maturities Within One Year Carrying Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearCarryingValue	61178000
CY2022Q4	rcel	Available For Sale Securities Debt Maturities After One Year Through Three Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearThroughThreeYearsAmortizedCost	6933000
CY2022Q4	rcel	Available For Sale Securities Debt Maturities After One Year Through Three Years Carrying Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearThroughThreeYearsCarryingValue	6930000
CY2023	us-gaap	Debt Securities Trading Unrealized Gain DebtSecuritiesTradingUnrealizedGain	100000
CY2023	us-gaap	Debt Securities Trading Unrealized Loss DebtSecuritiesTradingUnrealizedLoss	5000
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-95000
CY2022	us-gaap	Debt Securities Trading Unrealized Gain DebtSecuritiesTradingUnrealizedGain	8000
CY2022	us-gaap	Debt Securities Trading Unrealized Loss DebtSecuritiesTradingUnrealizedLoss	434000
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	426000
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	390000
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	698000
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	390000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	698000
CY2023	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0
CY2022	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0
CY2023Q1	rcel	Increase In Operating Lease Rou Assets And Operating Lease Liabilities IncreaseInOperatingLeaseRouAssetsAndOperatingLeaseLiabilities	1100000
CY2023Q2	rcel	Increase In Operating Lease Rou Assets And Operating Lease Liabilities IncreaseInOperatingLeaseRouAssetsAndOperatingLeaseLiabilities	1100000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	929000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	775000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	101000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	51000
CY2023	us-gaap	Lease Cost LeaseCost	1030000
CY2022	us-gaap	Lease Cost LeaseCost	826000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	815000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	803000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2440000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	851000
CY2023Q4	rcel	Right Of Use Assets RightOfUseAssets	2440000
CY2022Q4	rcel	Right Of Use Assets RightOfUseAssets	851000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	895000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	612000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1702000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	306000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2597000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	918000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M21D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y5M8D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0875
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0671
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1079000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	738000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	684000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	318000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	190000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3009000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	412000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2597000
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3683000
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1131000
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	878000
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	384000
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1035000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	610000
CY2023Q4	us-gaap	Inventory Net InventoryNet	5596000
CY2022Q4	us-gaap	Inventory Net InventoryNet	2125000
CY2023	rcel	Excess And Obsolete Inventory Related Charges ExcessAndObsoleteInventoryRelatedCharges	-221000
CY2022	rcel	Excess And Obsolete Inventory Related Charges ExcessAndObsoleteInventoryRelatedCharges	-375000
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	616000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	129000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	487000
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	558000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	93000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	465000
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	4000
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	35000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	58000
CY2023Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	227000
CY2022Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	168000
CY2023Q4	rcel	Lease Deposits Current LeaseDepositsCurrent	38000
CY2022Q4	rcel	Lease Deposits Current LeaseDepositsCurrent	110000
CY2022Q4	rcel	Contract Costs Current ContractCostsCurrent	252000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	18000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	127000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1659000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1578000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	38000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	38000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	37000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	37000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	37000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	246000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	433000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2432000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2152000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1877000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1200000
CY2023	us-gaap	Depreciation Depreciation	597000
CY2022	us-gaap	Depreciation Depreciation	510000
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-83000
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1376000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	921000
CY2023Q4	us-gaap	Deposit Assets DepositAssets	155000
CY2022Q4	us-gaap	Deposit Assets DepositAssets	25000
CY2023Q4	rcel	Other Long Term Assets Long Term Prepaids OtherLongTermAssetsLongTermPrepaids	148000
CY2022Q4	rcel	Other Long Term Assets Long Term Prepaids OtherLongTermAssetsLongTermPrepaids	97000
CY2023Q4	rcel	Other Long Term Assets Non Current OtherLongTermAssetsNonCurrent	52000
CY2023Q4	rcel	Other Long Term Assets OtherLongTermAssets	355000
CY2022Q4	rcel	Other Long Term Assets OtherLongTermAssets	122000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	895000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	612000
CY2022Q4	rcel	Barda Deferred Costs BARDADeferredCosts	194000
CY2023Q4	rcel	Cosmotec Deferred Revenue CosmotecDeferredRevenue	33000
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	338000
CY2022Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	184000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1266000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	990000
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	us-gaap	Revenues Revenues	50143000
CY2022	us-gaap	Revenues Revenues	34421000
CY2023	us-gaap	Revenues Revenues	50143000
CY2022	us-gaap	Revenues Revenues	34421000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	7780000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	6041000
CY2023	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. The Company expenses legal costs associated with loss contingencies as incurred. As of December 31, 2023, the Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any outstanding or threatened litigation that would have a material impact to the financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25682078
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25682078
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25208436
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25208436
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	rcel	Number Of Executives Having Administrative Changes To Employment Agreements NumberOfExecutivesHavingAdministrativeChangesToEmploymentAgreements	5
CY2023	rcel	Modifications On Administrative Changes To Employment Agreements Description ModificationsOnAdministrativeChangesToEmploymentAgreementsDescription	Changes included clarification that equity awards are inclusive of options and RSUs, and a change in the post-termination exercise period from 6-months to 3-months.
CY2023Q4	rcel	Number Of Executives Received Employment Agreements For First Time As Result Of Promotion NumberOfExecutivesReceivedEmploymentAgreementsForFirstTimeAsResultOfPromotion	4
CY2023	rcel	Share Based Compensation Expense Related To Equity ShareBasedCompensationExpenseRelatedToEquity	8400000
CY2022	rcel	Share Based Compensation Expense Related To Equity ShareBasedCompensationExpenseRelatedToEquity	7000000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8384000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6998000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2235446
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.47
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M15D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1530263
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	972193
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.52
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	166675
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.74
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	241535
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	20.95
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	109271
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.53
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2690158
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.91
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M1D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1530263
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1164791
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.96
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y11M23D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	587632
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2690158
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	12.91
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y8M1D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1530263
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	460518
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.30
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	57798
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.17
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	235059
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	6.37
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	48125
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	5.67
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	235132
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	8.29
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.66
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.14
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.72
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.13
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.71
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.03
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0351
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0444
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0142
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0394
CY2023Q2	rcel	Employee Stock Purchases Plan Effective Date EmployeeStockPurchasesPlanEffectiveDate	2023-07-01
CY2023Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	1000000
CY2023	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	72319
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-44691000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-26764000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	9376000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	135000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35315000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26629000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	66000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	36000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	66000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	36000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7416000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5592000
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	66000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	35000
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	375000
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	5000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	774000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	719000
CY2023	rcel	Effective Income Tax Rate Reconciliation Fair Value Change In Debt And Warrants EffectiveIncomeTaxRateReconciliationFairValueChangeInDebtAndWarrants	494000
CY2023	rcel	Effective Income Tax Rate Reconciliation Foreign Exchange Gain Loss On Intercompany Trade Balances EffectiveIncomeTaxRateReconciliationForeignExchangeGainLossOnIntercompanyTradeBalances	-2354000
CY2023	rcel	Effective Income Tax Rate Reconciliation Gain Of Transfer Of Intellectual Property EffectiveIncomeTaxRateReconciliationGainOfTransferOfIntellectualProperty	2804000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	554000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-30000
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-847000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5616000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4899000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36000
CY2023Q4	rcel	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	618000
CY2022Q4	rcel	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	229000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	11000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	6000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	624000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	240000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	3000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2714000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1833000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	12000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3763000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3405000
CY2023Q4	rcel	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	-657000
CY2022Q4	rcel	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	-247000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5357000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2215000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	50438000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	48413000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	992000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	630000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63933000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	56746000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63309000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56506000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	624000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	240000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63300000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56500000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35381000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26665000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25331000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25331000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25000000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25000000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.4
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.4
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.07
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.07
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	99106
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17927
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1200000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1000000
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	171000
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	258000
CY2023Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	3800000
CY2022Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	1300000
CY2023	rcel	Payout Of Deferred Compensation Liability PayoutOfDeferredCompensationLiability	950000
CY2022	rcel	Payout Of Deferred Compensation Liability PayoutOfDeferredCompensationLiability	950000
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	81052
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	253048
CY2023	rcel	Deferred Compensation Arrangement With Individual Shares Vested DeferredCompensationArrangementWithIndividualSharesVested	99106
CY2022	rcel	Deferred Compensation Arrangement With Individual Shares Vested DeferredCompensationArrangementWithIndividualSharesVested	17927
CY2023	rcel	Deferred Compensation Arrangement With Individual Vested Redemption Value DeferredCompensationArrangementWithIndividualVestedRedemptionValue	1100000
CY2022	rcel	Deferred Compensation Arrangement With Individual Vested Redemption Value DeferredCompensationArrangementWithIndividualVestedRedemptionValue	127000

Files In Submission

Name	View Source	Status
0000950170-24-018748-index-headers.html	Edgar Link	pending
0000950170-24-018748-index.html	Edgar Link	pending
0000950170-24-018748.txt	Edgar Link	pending
0000950170-24-018748-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img178749779_0.jpg	Edgar Link	pending
img30181513_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
rcel-20231231.htm	Edgar Link	pending
rcel-20231231.xsd	Edgar Link	pending
rcel-ex10_30.htm	Edgar Link	pending
rcel-ex10_31.htm	Edgar Link	pending
rcel-ex10_32.htm	Edgar Link	pending
rcel-ex10_33.htm	Edgar Link	pending
rcel-ex10_34.htm	Edgar Link	pending
rcel-ex10_35.htm	Edgar Link	pending
rcel-ex10_36.htm	Edgar Link	pending
rcel-ex10_37.htm	Edgar Link	pending
rcel-ex10_38.htm	Edgar Link	pending
rcel-ex10_39.htm	Edgar Link	pending
rcel-ex10_40.htm	Edgar Link	pending
rcel-ex10_41.htm	Edgar Link	pending
rcel-ex10_42.htm	Edgar Link	pending
rcel-ex23_1.htm	Edgar Link	pending
rcel-ex31_1.htm	Edgar Link	pending
rcel-ex31_2.htm	Edgar Link	pending
rcel-ex32_1.htm	Edgar Link	pending
rcel-ex97_1.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
rcel-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RCEL
AVITA Medical, Inc. Stock $rcel

2024 Q1 Form 10-K Financial Statement

#000095017024018748 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RCEL AVITA Medical, Inc. Stock $rcel

2024 Q1 Form 10-K Financial Statement

#000095017024018748 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RCEL
AVITA Medical, Inc. Stock $rcel